About Penumbra, Inc.
https://www.penumbrainc.comPenumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally.
CEO
Adam Elsesser
Compensation Summary
(Year 2024)
Salary $628,846
All Other Compensation $1,621
Total Compensation $630,467
Industry Medical - Devices
Sector Healthcare
Went public September 18, 2015
Method of going public IPO
Full time employees 4,500
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-11-16 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 224
Showing Top 3 of 224
Ratings Snapshot
Rating : B-
Discounted Cash Flow 1
Return On Equity 4
Return On Assets 5
Debt To Equity 3
Price To Earnings 1
Price To Book 1
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 7
Outperform 3
Overweight 3
Equal Weight 1
Showing Top 6 of 14
Price Target
Target High $388
Target Low $290
Target Median $350
Target Consensus $347.75
Institutional Ownership
FMR LLC
Shares:5.89M
Value:$1.85B
BLACKROCK INC.
Shares:4.26M
Value:$1.33B
BLACKROCK, INC.
Shares:4.17M
Value:$1.31B
Summary
% Of Shares Owned 79.39%
Total Number Of Holders 500
Showing Top 3 of 500
Market Cap $12.36 B
52w High $325.02
52w Low $221.26
P/E 74.98
Volume 418.85K
Outstanding Shares 39.16M
About Penumbra, Inc.
https://www.penumbrainc.comPenumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $354.69M ▲ | $191.58M ▲ | $45.85M ▲ | 12.93% ▼ | $1.17 | $55.15M ▲ |
| Q2-2025 | $339.45M ▲ | $183.18M ▲ | $45.27M ▲ | 13.34% ▲ | $1.17 ▲ | $51.14M ▲ |
| Q1-2025 | $324.14M ▲ | $175.53M ▲ | $39.22M ▲ | 12.1% ▲ | $1.02 ▲ | $49.2M ▲ |
| Q4-2024 | $315.52M ▲ | $167.95M ▲ | $33.68M ▲ | 10.68% ▲ | $0.88 ▲ | $49.06M ▲ |
| Q3-2024 | $301.04M | $164.94M | $29.53M | 9.81% | $0.76 | $44.26M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $470.3M ▲ | $1.74B ▲ | $385.67M ▲ | $1.36B ▲ |
| Q2-2025 | $424.56M ▲ | $1.67B ▲ | $380.86M ▲ | $1.29B ▲ |
| Q1-2025 | $378.85M ▲ | $1.59B ▲ | $380.43M ▼ | $1.21B ▲ |
| Q4-2024 | $340.13M ▲ | $1.53B ▲ | $382.25M ▲ | $1.15B ▲ |
| Q3-2024 | $291.02M | $1.48B | $374.84M | $1.1B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $45.85M ▲ | $58.26M ▲ | $-162.86M ▼ | $3.95M ▼ | $-100.74M ▼ | $42.01M ▲ |
| Q2-2025 | $45.27M ▲ | $44.95M ▼ | $-15.58M ▼ | $14.82M ▲ | $45.71M ▼ | $29.37M ▼ |
| Q1-2025 | $39.22M ▲ | $48.97M ▼ | $-502K ▲ | $2.71M ▼ | $51.65M ▲ | $35.5M ▼ |
| Q4-2024 | $33.68M ▲ | $51.11M ▼ | $-10.96M ▼ | $6.07M ▲ | $43.93M ▲ | $45.74M ▼ |
| Q3-2024 | $29.53M | $56.47M | $35.72M | $-100.55M | $-7.86M | $51.02M |
Revenue by Products
| Product | Q4-2022 | Q1-2023 | Q2-2023 | Q3-2023 |
|---|---|---|---|---|
 Neuro | $90.00M ▲ | $100.00M ▲ | $110.00M ▲ | $170.00M ▲ |
 Peripheral Vascular | $130.00M ▲ | $140.00M ▲ | $150.00M ▲ | $100.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Other NonUS | $70.00M ▲ | $80.00M ▲ | $80.00M ▲ | $70.00M ▼ |
 UNITED STATES | $250.00M ▲ | $280.00M ▲ | $260.00M ▼ | $260.00M ▲ |
CEO
Adam Elsesser
Compensation Summary
(Year 2024)
Salary $628,846
All Other Compensation $1,621
Total Compensation $630,467
Industry Medical - Devices
Sector Healthcare
Went public September 18, 2015
Method of going public IPO
Full time employees 4,500
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-11-16 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 224
Showing Top 3 of 224
Ratings Snapshot
Rating : B-
Discounted Cash Flow 1
Return On Equity 4
Return On Assets 5
Debt To Equity 3
Price To Earnings 1
Price To Book 1
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 7
Outperform 3
Overweight 3
Equal Weight 1
Showing Top 6 of 14
Price Target
Target High $388
Target Low $290
Target Median $350
Target Consensus $347.75
Institutional Ownership
FMR LLC
Shares:5.89M
Value:$1.85B
BLACKROCK INC.
Shares:4.26M
Value:$1.33B
BLACKROCK, INC.
Shares:4.17M
Value:$1.31B
Summary
% Of Shares Owned 79.39%
Total Number Of Holders 500
Showing Top 3 of 500